

DAFTAR PUSTAKA

- A M E R I C A N D I A B E T E S A S S O C I A T I O N S T A N D A R D S O F
M E D I C A L C A R E I N D I A B E T E S - 2 0 1 7 .* (n.d.).
- Abdelrazig, O. A. O. (2021). *PERBANDINGAN EFEKTIVITAS PENGGUNAAN OBAT ANTIDIABETIK TUNGGAL DAN KOMBINASI PADA PASIEN DIABETES MELITUS TIPE II DI RUMAH SAKIT NASIONAL AL AMAL SUDAN.*
- Alhadramy, M. S. (2016). Diabetes and oral therapies. *Journal of Taibah University Medical Sciences*, 11(4), 317–329.
<https://doi.org/10.1016/j.jtumed.2016.02.001>
- AMANDARI, E. (2019). SGLT-2 INHIBITOR: PILIHAN TERAPI BARU UNTUK PENDERITA DIABETES MELITUS TIPE 2. *Jurnal Farmasi Udayana*, 7. <https://doi.org/10.24843/JFU.2019.v08.i01.p02>
- Baumblatt, J., Fryar, C., Gu, Q., & Ashman, J. (2024). *Prevalence of Total, Diagnosed, and Undiagnosed Diabetes in Adults: United States, August 2021–August 2023.* <https://doi.org/10.15620/cdc/165794>
- Brunton, L. L., Hilal-Dandan, R., & Knollmann, B. C. (2018). *Goodman & Gilman's: The Pharmacological Basic of Therapeutics.* McGraw-Hill Education.
- Chatterjee, S., Peters, S. A. E., Woodward, M., Mejia Arango, S., Batty, G. D., Beckett, N., Beiser, A., Borenstein, A. R., Crane, P. K., Haan, M., Hassing, L. B., Hayden, K. M., Kiyohara, Y., Larson, E. B., Li, C.-Y., Ninomiya, T., Ohara, T., Peters, R., Russ, T. C., ... Huxley, R. R. (2016). Type 2 Diabetes as a Risk Factor for Dementia in Women Compared With Men: A Pooled Analysis of 2.3 Million People Comprising More Than 100,000 Cases of Dementia. *Diabetes Care*, 39(2), 300–307. <https://doi.org/10.2337/dc15-1588>
- Chaudhury, A., Duvoor, C., Reddy Dendi, V. S., Kraleti, S., Chada, A., Ravilla, R., Marco, A., Shekhawat, N. S., Montales, M. T., Kuriakose, K., Sasapu, A., Beebe, A., Patil, N., Musham, C. K., Lohani, G. P., & Mirza, W. (2017). Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management. *Frontiers in Endocrinology*, 8.
<https://doi.org/10.3389/fendo.2017.00006>
- DeSa, T., & Gong, T. (2021). SGLT2 inhibitors: a new pillar of the heart failure regimen. *Reviews in Cardiovascular Medicine*, 22(4).
<https://doi.org/10.31083/j.rcm2204133>
- Dewi, R., Wati, A., & Lestari, D. (2023). *Archives Pharmacia Volume (Vol. 5).*

Diabetes Technology: Standards of Medical Care in Diabetes—2022. (2022). *Diabetes Care*, 45, S97–S112. <https://doi.org/10.2337/dc22-S007>

Endokrinologi Indonesia PEDOMAN PENGELOLAAN DAN PENCEGAHAN DIABETES MELITUS TIPE, P. (n.d.). *PEDOMAN PENGELOLAAN DAN PENCEGAHAN DIABETES MELITUS TIPE 2 DEWASA DI INDONESIA-2021 PERKENI i Penerbit PB. PERKENI*.

Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes: Standards of Care in Diabetes—2024. (2024). *Diabetes Care*, 47, S77–S110. <https://doi.org/10.2337/dc24-S005>

Galicia-Garcia, U., Benito-Vicente, A., Jebari, S., Larrea-Sebal, A., Siddiqi, H., Uribe, K. B., Ostolaza, H., & Martín, C. (2020). Pathophysiology of type 2 diabetes mellitus. In *International Journal of Molecular Sciences* (Vol. 21, Issue 17, pp. 1–34). MDPI AG. <https://doi.org/10.3390/ijms21176275>

Gede Tina Sujayanti, L., Dian Marani Kurnianta, P., Studi Sarjana Farmasi Sekolah Tinggi Farmasi Mahaganessa, P., Studi Diploma, P., & Sekolah Tinggi Farmasi Mahaganessa, F. (2022). 2 | *Jurnal Ilmiah Mahaganessa* (Vol 11 No. 1 2022) Pola Penggunaan Antidiabetes Oral pada Pasien Diabetes Melitus Tipe II di Rumah Sakit X Gianyar Oral Antidiabetic Drugs Use in Patients with Type 2 Diabetes Mellitus at Hospital X Gianyar. *JIM: Jurnal Ilmiah Mahaganessa*, 1(1), 12–17.

Goyal, R., Singhal, M., & Jialal, I. (2025). *Type 2 Diabetes*.

Gronroos, N., Swift, C., Frazer, M., Sargent, A., Leszko, M., Buysman, E., Alvarez, S., Dunn, T., & No-one, J. (2024). Real-World HbA1c Changes Among Type 2 Diabetes Mellitus Patients Initiating Treatment With a 1.0 Mg Weekly Dose of Semaglutide for Diabetes. *Journal of Health Economics and Outcomes Research*, 118–124. <https://doi.org/10.36469/jheor.2024.124111>

Gupta, S., Jha, S., Rani, S., Arora, P., & Kumar, S. (2024). Medicinal Perspective of 2,4-Thiazolidinediones Derivatives: An Insight into Recent Advancements. *ChemistryOpen*, 13(11). <https://doi.org/10.1002/open.202400147>

Hakim Kurniawan, A., & Naufal Fauzan, M. (n.d.). TREATMENT PATTERN AND COST-EFFECTIVENESS ANALYSIS OF ORAL HYPOGLYCEMICS FOR TYPE 2 DIABETES MELLITUS OUTPATIENTS AT REGIONAL GENERAL HOSPITAL, INDONESIA. In *Malaysian Journal of Public Health Medicine* (Vol. 2022, Issue 2).

- Hendriks, A. M., Schrijnders, D., Kleefstra, N., de Vries, E. G. E., Bilo, H. J. G., Jalving, M., & Landman, G. W. D. (2019). Sulfonylurea derivatives and cancer, friend or foe? *European Journal of Pharmacology*, 861, 172598. <https://doi.org/10.1016/j.ejphar.2019.172598>
- Himanshu, D., Ali, W., & Wamique, M. (2020). Type 2 diabetes mellitus: pathogenesis and genetic diagnosis. *Journal of Diabetes & Metabolic Disorders*, 19(2), 1959–1966. <https://doi.org/10.1007/s40200-020-00641-x>
- International Diabetes Federation. (2021). *IDF Diabetes Atlas, 10th edition* (10th ed.). International Diabetes Federation.
- Introduction. (2015). In *Diabetes Care* (Vol. 38, pp. S1–S2). American Diabetes Association Inc. <https://doi.org/10.2337/dc15-S001>
- Ivana, K., Luthfiyani Citra Pradana, D., & Ayu Aprilia, C. (n.d.). *NARRATIVE REVIEW: COST-EFFECTIVENESS ANALYSIS OF BIGUANIDE AND SULFONYLUREA FOR HOSPITALIZED PATIENT WITH TYPE 2 DIABETES MELLITUS* (Vol. 1, Issue 1).
- Katzung, B. G. (2021). *Basic and Clinical Pharmacology* (15th ed.). McGraw Hill Education.
- Kebijakan Pembangunan, B., Kementerian, K., & Ri, K. (n.d.). *DALAM ANGKA TIM PENYUSUN SKI 2023 DALAM ANGKA KEMENTERIAN KESEHATAN REPUBLIK INDONESIA*.
- Kim, H.-J., & Kim, K. (2022). Blood Pressure Target in Type 2 Diabetes Mellitus. *Diabetes & Metabolism Journal*, 46(5), 667–674. <https://doi.org/10.4093/dmj.2022.0215>
- Kim, N. H., Moon, J. S., Lee, Y., Cho, H. C., Kwak, S. H., Lim, S., Moon, M. K., Kim, D., Kim, T. H., Ko, E., Lee, J., & Kim, S. G. (2024). Efficacy and tolerability of initial triple combination therapy with metformin, dapagliflozin and saxagliptin compared with stepwise add-on therapy in drug-naïve patients with type 2 diabetes (<scp>TRIPLE</scp> - <scp>AXEL</scp> study): A multicentre, randomized, 104-week, open-label, active-controlled trial. *Diabetes, Obesity and Metabolism*, 26(9), 3642–3652. <https://doi.org/10.1111/dom.15705>
- Laporan Riskesdas 2018 Nasional*. (n.d.).
- Li, T., Quan, H., Zhang, H., Lin, L., Lin, L., Ou, Q., & Chen, K. (2021). Type 2 diabetes is more predictable in women than men by multiple anthropometric and biochemical measures. *Scientific Reports*, 11(1), 6062. <https://doi.org/10.1038/s41598-021-85581-z>

- Mpila, D. A., Wiyono, W. I., & Lolo, W. A. (2023). Hubungan Tingkat Kepatuhan Minum Obat dengan Kadar Gula Darah dan Kualitas Hidup Pasien Diabetes Melitus Tipe 2 di Klinik Imanuel Manado. *Medical Scope Journal*, 6(1), 116–123. <https://doi.org/10.35790/msj.v6i1.51696>
- Naha, S., Gardner, M. J., Khangura, D., Kurukulasuriya, L. R., & Sowers, J. R. (2021). *Hypertension in Diabetes*.
- Patil, P., Mandal, S., Tomar, S. K., & Anand, S. (2015). Food protein-derived bioactive peptides in management of type 2 diabetes. *European Journal of Nutrition*, 54(6), 863–880. <https://doi.org/10.1007/s00394-015-0974-2>
- Profil_Kesehatan_Kota_Bekasi_2019*. (n.d.).
- Profil_Kesehatan_Kota_Bekasi_2020*. (n.d.).
- Punthakee, Z., Goldenberg, R., & Katz, P. (2018). Definition, Classification and Diagnosis of Diabetes, Prediabetes and Metabolic Syndrome. *Canadian Journal of Diabetes*, 42, S10–S15. <https://doi.org/10.1016/j.cjcd.2017.10.003>
- Qian, D., Zhang, T., Zheng, P., Liang, Z., Wang, S., Xie, J., Zhao, L., Zhang, Y., & Situ, B. (2018). Comparison of Oral Antidiabetic Drugs as Add-On Treatments in Patients with Type 2 Diabetes Uncontrolled on Metformin: A Network Meta-Analysis. *Diabetes Therapy*, 9(5), 1945–1958. <https://doi.org/10.1007/s13300-018-0482-5>
- Ramadhani, P., Oktavia, S., & Adiningsih, V. L. (2025). IDENTIFICATION OF DRUG-RELATED PROBLEMS (DRPs) IN GERIATRIC PATIENTS WITH TYPE 2 DIABETES MELLITUS AT THE INTERNAL MEDICINE INPATIENT INSTALLATION OF DR. M. DJAMIL CENTRAL GENERAL HOSPITAL PADANG, INDONESIA. *Www.Wjpps.Com* | , 14, 1210. <https://doi.org/10.20959/wjpr20253-35476>
- Roman, G., & Pantea Stoian, A. (2021). Cardiovascular Risk/Disease in Type 2 Diabetes Mellitus. In *Type 2 Diabetes - From Pathophysiology to Cyber Systems*. IntechOpen. <https://doi.org/10.5772/intechopen.97422>
- Soliman, A., De Sanctis, V., Alaaraj, N., & Hamed, N. (2020). The clinical application of metformin in children and adolescents: A short update. *Acta Biomedica*, 91(3), 1–15. <https://doi.org/10.23750/abm.v91i3.10127>
- Standards of Care in Diabetes-2023*. (2022). <https://diabetesjournals.org/care>
- Tiwary, N., Sharma, N., Singh, S., Behl, T., & Zahoor, I. (2024). Understanding the Pharmacological and Nanotechnological Facets of Dipeptidyl Peptidase-4 Inhibitors in Type II Diabetes Mellitus: a Paradigm in Therapeutics. *BioNanoScience*, 14(1), 211–229. <https://doi.org/10.1007/s12668-023-01234-7>

- Tresnawati, N. A., Hany Yusmaini, Mila Citrawati, & Erna Harfiani. (2024). Cost-effectiveness comparison of antidiabetic drugs combination therapy metformin-glimepiride and acarbose-glimepiride. *Jurnal Ilmiah Farmasi*, 20(1), 118–128. <https://doi.org/10.20885/jif.vol20.iss1.art9>
- Yang, H. K., Lee, S.-H., Shin, J., Choi, Y.-H., Ahn, Y.-B., Lee, B.-W., Rhee, E. J., Min, K. W., & Yoon, K.-H. (2019). Acarbose Add-on Therapy in Patients with Type 2 Diabetes Mellitus with Metformin and Sitagliptin Failure: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. *Diabetes & Metabolism Journal*, 43(3), 287. <https://doi.org/10.4093/dmj.2018.0054>
- Zheng, Y., Ley, S. H., & Hu, F. B. (2018). Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. *Nature Reviews Endocrinology*, 14(2), 88–98. <https://doi.org/10.1038/nrendo.2017.151>